Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
Julien Denis le SèveAlexis F GuédonStéphanie BordenaveChristian AgardJérôme ConnaultMarc-Antoine PistoriusGaelle QuéreuxOlivier EspitiaPublished in: Thrombosis and haemostasis (2023)
The prevalence of VTE was 14.2% under ICIs. IRAE and combine treatment of nivolumab and ipilimumab were associated with VTE. The pathophysiological mechanisms are multiple and complex with a possible link to aberrant activation of the immune system.